Bleakley Financial Group LLC Raises Stock Position in Cencora, Inc. $COR

Bleakley Financial Group LLC increased its stake in Cencora, Inc. (NYSE:COR) by 31.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 28,102 shares of the company’s stock after purchasing an additional 6,755 shares during the quarter. Bleakley Financial Group LLC’s holdings in Cencora were worth $9,492,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in COR. Oakworth Capital Inc. purchased a new stake in Cencora in the fourth quarter worth approximately $26,000. Elyxium Wealth LLC purchased a new stake in Cencora in the fourth quarter worth approximately $27,000. Archer Investment Corp boosted its holdings in Cencora by 134.3% in the fourth quarter. Archer Investment Corp now owns 82 shares of the company’s stock worth $28,000 after purchasing an additional 47 shares during the last quarter. IAG Wealth Partners LLC bought a new position in Cencora in the third quarter worth approximately $30,000. Finally, Cloud Capital Management LLC bought a new position in Cencora in the third quarter worth approximately $31,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Performance

Shares of NYSE:COR opened at $275.01 on Tuesday. Cencora, Inc. has a 52 week low of $244.82 and a 52 week high of $377.54. The stock has a market capitalization of $53.51 billion, a P/E ratio of 21.09, a PEG ratio of 1.27 and a beta of 0.64. The firm has a fifty day simple moving average of $304.15 and a two-hundred day simple moving average of $336.24. The company has a quick ratio of 0.59, a current ratio of 0.95 and a debt-to-equity ratio of 3.40.

Cencora (NYSE:COR) last issued its quarterly earnings data on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). Cencora had a return on equity of 135.20% and a net margin of 0.78%.The business had revenue of $78.36 billion during the quarter, compared to analysts’ expectations of $81.09 billion. During the same period in the previous year, the business earned $4.42 earnings per share. The business’s quarterly revenue was up 3.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. On average, analysts expect that Cencora, Inc. will post 17.79 earnings per share for the current fiscal year.

Cencora declared that its board has approved a share repurchase program on Thursday, May 21st that permits the company to buyback $2.00 billion in shares. This buyback authorization permits the company to purchase up to 3.9% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s management believes its shares are undervalued.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Shareholders of record on Friday, May 15th will be paid a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. The ex-dividend date of this dividend is Friday, May 15th. Cencora’s dividend payout ratio (DPR) is presently 18.40%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on COR. Leerink Partners reiterated an “outperform” rating on shares of Cencora in a research report on Tuesday, March 17th. Robert W. Baird decreased their price objective on shares of Cencora from $420.00 to $339.00 and set an “outperform” rating on the stock in a research report on Thursday, May 7th. UBS Group raised their target price on shares of Cencora from $410.00 to $412.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. JPMorgan Chase & Co. raised their target price on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday, February 10th. Finally, Barclays raised their target price on shares of Cencora from $400.00 to $425.00 and gave the company an “overweight” rating in a research note on Friday, February 13th. Twelve investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $380.25.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.